LifeVantage outlines $225M–$240M fiscal 2026 revenue target as LoveBiome integration advances

Earnings Call Insights: LifeVantage Corporation (LFVN) Q1 2026

MANAGEMENT VIEW

* Steve Fife, President and CEO, described the quarter as “truly been transformational,” highlighting the closure of the LoveBiome acquisition, which he said positions LifeVantage “at the forefront of a rapidly growing wellness market.” He emphasized that the integration brings together “two passionate consultant communities” and aligns with their focus on nutrigenomic innovation.
* Fife reported net revenue of $47.6 million, “up fractionally from a year ago,” and adjusted EBITDA of $3.9 million, “down $500,000 versus last year due to lower contribution margin, partially offset by lower SG&A.”
* On the LoveBiome acquisition, Fife stated, “This transaction represents far more than just additional products in our portfolio. It’s about positioning LifeVantage squarely within one of the fastest-growing segments in wellness, gut microbiome health.” He noted the integration is “essentially complete,” with onboarding of personnel, including founder Kelly Olsen, and positive early consultant feedback.
* Fife referenced the company’s U.S. Momentum Academy event in Dallas, noting “nearly 2,000 registered, making it one of our largest Momentum Academy events ever,” and said consultant community integration “exceeded our expectations.”
* Fife highlighted progress on the Shopify partnership, mentioning “great progress with the design, content and development aspects of our new e-commerce platform as we work towards a pilot this fiscal year and later our full rollout.”
* CFO Carl Aure stated, “For the first quarter of fiscal 2026, we delivered net revenue of $47.6 million, which was up 0.7% compared to $47.2 million in the first quarter of fiscal 2025.”
* Aure noted adjusted non-GAAP net income was $2.3 million or $0.18 per fully diluted share compared to $1.9 million or $0.15 per share in the prior year period.

OUTLOOK

* The company reiterated full-year fiscal 2026 revenue guidance of $225 million to $240 million, including the expected contribution from LoveBiome.
* Adjusted non-GAAP EBITDA is expected in the range of $23 million to $26 million and adjusted non-GAAP EPS in the range of $1 to $1.15 per share.
* Management anticipates “revenue in the second half of fiscal 2026 will be higher than the first half due to the seasonality associated with our MindBody product line and the impact of the LoveBiome acquisition.”

FINANCIAL RESULTS

* Net revenue for Q1 2026 was $47.6 million, reflecting “increased sales of our MB GLP-1 system, offset by lower sales of Protandim and TrueScience product line as well as decrease in total active accounts.”
* Revenues in Japan increased 2.6% on a constant currency basis, driven by the launch of the MindBody GLP-1 system.
* Gross margin for the quarter was 79.5%, “down 40 basis points compared to the prior year period, primarily due to increases in shipping and warehouse related expenses.”
* Commissions and incentive expense as a percentage of revenue was 43.5% in the first quarter compared to 43% in the prior year period.
* Non-GAAP adjusted SG&A expense was $14.6 million, roughly flat year-over-year.
* Adjusted non-GAAP operating income was $2.5 million, and adjusted EBITDA was $3.9 million or 8.2% of revenues.
* Cash at quarter-end was $13.1 million with no debt, and the company repurchased 44,000 shares at an average of $13 per share.
* A quarterly cash dividend of $0.045 per share was announced, payable December 15, 2025.

Q&A

* Douglas Lane, Water Tower Research LLC, asked about the September quarter versus expectations. Steve Fife responded, “Q1 is historically our low quarter… a little softer than maybe than what we thought, but not alarming at all.”
* Lane inquired about the impact of the LoveBiome announcement prior to close. Fife stated, “There was 0 revenue contribution from LoveBiome. We didn’t close the transaction until October 1.”
* Lane questioned the integration process and timing for full benefit realization. Fife replied, “Effective November 1, we have really integrated all aspects of our business… and now that integration piece is behind us, and we can focus more of our attention on really optimizing now the combined consultant base and customer base of the 2 companies.”
* Lane probed the gut health science opportunity. Fife explained the recent in vitro test on P84, noting “we identified 14 peptides in our body that are responsible for regulating, repairing and restoring overall gut health that were activated.”

SENTIMENT ANALYSIS

* Analysts raised recurring questions about revenue trends, integration timing, and the scientific differentiation of new products, displaying a neutral tone with some cautious probing.
* Management expressed optimism and confidence, particularly regarding the integration and growth trajectory, as Fife stated, “The reception to both sides… of this partnership has been tremendous.”
* Compared to the previous quarter, the analyst tone remained consistent, while management’s tone shifted to a more assertive confidence following the completion of the LoveBiome acquisition and reporting of early positive integration indicators.

QUARTER-OVER-QUARTER COMPARISON

* The current quarter saw the completion and integration of the LoveBiome acquisition, whereas the previous quarter focused on announcing the acquisition and its expected strategic benefits.
* Guidance for fiscal 2026 was reiterated, with no change in revenue or profit targets.
* There was a modest increase in revenue and EPS compared to the prior year’s first quarter, but both gross margin and adjusted EBITDA margin declined slightly due to higher shipping, warehouse, and commission expenses.
* Management’s confidence appeared higher in the current quarter, emphasizing successful integration, operational progress, and early signs of synergy realization.
* Analysts maintained focus on integration, product performance, and the revenue impact of the LoveBiome transaction.

RISKS AND CONCERNS

* Management cited seasonality as a recurring challenge, with Q1 described as “historically our low quarter.”
* Revenue softness and lower consultant activity during the summer months were discussed.
* Gross margin pressure from increased shipping and warehouse expenses was acknowledged.
* The company noted the need for effective training and onboarding to fully realize the benefits of the LoveBiome acquisition.

FINAL TAKEAWAY

Management highlighted the successful and rapid integration of LoveBiome, early positive momentum from combined consultant communities, and progress on technology upgrades as key drivers for sustained growth. The company reiterated its fiscal 2026 revenue and profit guidance, signaling confidence in capturing opportunities within the expanding gut health and wellness market. Investors were reassured of operational stability, ongoing synergy realization, and a balanced capital allocation approach as LifeVantage advances its growth strategy.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/lfvn/earnings/transcripts]

MORE ON LIFEVANTAGE

* LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4837795-lifevantage-corporation-lfvn-q1-2026-earnings-call-transcript]
* LifeVantage Corporation (LFVN) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow [https://seekingalpha.com/article/4821669-lifevantage-corporation-lfvn-presents-at-h-c-wainwright-27th-annual-global-investment]
* LifeVantage: Downgrading On Disappointing Results And Outlook - Hold [https://seekingalpha.com/article/4820316-lifevantage-stock-downgrading-on-disappointing-q4-results-and-outlook-hold]
* LifeVantage Q1 2026 Earnings Preview [https://seekingalpha.com/news/4513206-lifevantage-q1-2026-earnings-preview]
* LifeVantage falls after earnings miss, LoveBiome revenue outlook unclear [https://seekingalpha.com/news/4492612-lifevantage-falls-after-earnings-miss-lovebiome-revenue-outlook-unclear]